Objective: We aimed to evaluate the prevalence of metabolic syndrome (MS) in a group of obese children and adolescents in Zhejiang in the south of China, and to compare risk factors such as insulin resistance, adiponectin level and impaired glucose tolerance (IGT) etc with that of simple obese group (SOB) and non-obese healthy group, and also to evaluate the effect of metformin and lifestyle intervention in MS group by up to a 3-month follow-up. Methods: Three hundred and forty eight moderately or severely obese adolescents aged between 7 and 16 years were enrolled. Oral glucose tolerance test (OGTT), biochemical indicators, blood pressure and body mass index (BMI) were assessed in all of them. Three subgroups were selected (MS group, SOB and healthy control). Adiponectin levels, Whole body insulin sensitive index (WBISI), homeostasis model of insulin resistance (HOMA-IR), plasma lipid and blood pressure were compared in these three groups. Thirty out of thirty-six MS subjects with age over 10 years received metformin treatment combined with lifestyle modification. Results: (1) The prevalence of MS was 10.34% among all obese subjects, which increased with the severity of obesity and reached 22.1% in severely obese children and adolescents. The occurrence of more than one complication reached 72.13%. The incidence of type 2 diabetes and IGT were 1.44 and 1.44% respectively. (2) BMI, waist-to-hip ratio (WHR) and HOMA-IR increased stepwise in the control group, SOB and MS group, whereas serum adiponectin and WBISI decreased stepwise (all Po0.01). Systolic pressure, triglyceride, total cholesterol, low-density lipoprotein cholesterol and postprandial 2-h blood glucose in the MS group increased significantly compared to those in control and SOBs (all Po0.01). A correlation analysis showed that serum levels of adiponectin and WBISI were associated with the components of MS (all Po0.05). (3) After metformin and lifestyle intervention, clinical symptoms were ameliorated, serum adiponectin levels were actually increased and HOMA-IR was dropped in 20/30 MS children who had finished a 3-months follow-up (all Po0.01). Conclusion: The prevalence of MS in severely obese children and adolescents in Zhejiang area has reached a high level. Insulin resistance and hypoadiponectinemia were found in these MS children. Metformin combined with lifestyle modification was confirmed to be efficient and safe in treating the obese adolescents with MS.
Introduction
The age-adjusted MS prevalence for adults in US was 23.7% according to third National Health and Nutrition Examination Survey (NHANES III). The number of people with MS increased with age, affecting more than 40% of people in their 60s and 70s. 1 However, there is not much information on the prevalence of MS in children and adolescents, especially in China. Metabolic syndrome (MS), a cluster of potent risk factors for atherosclerotic cardiovascular disease and type 2 diabetes mellitus in adults, is composed of insulin resistance, hypertension and dyslipidemia. 2, 3 Although MS is particularly important in adults, the pathological processes and risk factors associated with its development have been shown to begin during childhood. 4, 5 Like adults, obesity a major risk factor of insulin resistance plays a central role in childhood MS. Recently, adipocytokines have been suggested to mediate obesity-associated metabolic disorder and play an important role in MS. Adiponectin, one of the adipocytokines, which has been shown to have a close relationship with type2 diabetes mellitus and coronary artery disease in adults, 6, 7 is now of great interest in relationship to the childhood MS. 8 Interventions are imperative but not widely studied. Metformin has shown promise in ameliorate the blood sugar and improving insulin sensitivity, and is the only drug approved by American Diabetes Association (ADA) that can be used in children over 10 years old with type 2 diabetes, 9 but it is not widely used in children with MS.
This study was conducted to provide up-to-date estimates of the prevalence of MS in different degrees of obesity in Chinese obese children and adolescents and its relationship to adiponectin and insulin resistance. We also compared the independent risk factors such as adiponectin, hypertention and insulin resistant markers in MS groups, simple obese group (SOB) and healthy control. Moreover, we evaluated the effect of metformin treatment combined with lifestyle modification on MS by a 3-month follow-up.
Methods

Study population
Three hundred and forty-eight obese children and adolescents who were referred to our endocrinology department aged between 7 and 16 years old, with the complaint of obesity from August 2003 to September 2005, were included into our criteria.
Inclusion criteria. Subjects were eligible if they were healthy, and had a weight that was above the 97th percentile, and exceeded 30% (moderately obese) or 50% (severely obese) of their standard weight for their age and sex based on the national reference data in 1995, consistent with an accepted diagnosis of moderately or severely obesity in Chinese children. 10 Exclusion criteria were the known presence of diabetes or other endocrine metabolic or kidney diseases, and the use of medication that alters blood pressure or glucose or lipid metabolism. In order to exclude subjects with endocrine or metabolic disease, liver and kidney function, thyroid function, adrenocorticotropic hormone and cortisol levels were measured and evaluated. Computed tomography or magnetic resonance imaging scans were performed to exclude hypothalamic and pituitary disease. Bultrasound was used to detect liver and adrenal glands in all subjects.
Twenty-four of age-, sex-and puberty-matched healthy children and adolescents who were undergoing routine annual physical examinations in our child health department with weight at 25th-75th of the national reference data in 1995 were invited sequentially to take part in the study.
Written informed consent from parents and written assent from children (where appropriate) and adolescents were obtained. The protocol was approved by the Medical Ethics Committee of The Children's Hospital of Zhejiang University School of Medicine.
Definitions
The diagnosis criteria for MS were according to the suggestion of the Chinese Diabetes Association and the definition of Weiss' which were modified from those of the National Cholesterol Education Program's Adult Treatment Panel III(NCEP-ATPIII) and the World Health Organization. [11] [12] [13] Like adults, the children and adolescents in our study were classified as having MS if they met three or more of the following criteria for age and sex: central obese; a systolic or a diastolic blood pressure above the 95th percentile for age and sex; a triglyceride level above the 95th percentile or an low high-density lipoprotein cholesterol (HDL-C) level below the fifth percentile; and an impaired glucose tolerance (IGT) or a type 2 diabetes. In this study, high blood pressure was based on the percentile data of the seventh edition of Practical Pediatric Text Book of Zhu Fu-Tang. 10 High triglyceride was defined as a fasting level of triglyceride that was over1.7 mmol/l, and low HDL-C was defined as it was less than1.03 mmol/l. IGT was defined as a glucose level greater than 7.8 mmol/l but less than 11.1 mmol/l at 2 h. Type 2 diabetes diagnosis was according to the criteria of ADA in 1997 and World health Organization (WHO) in 1999. Non-alcoholic fatty liver disease (NAFLD) as one of the most common complications in obese subjects was diagnosed according to the references. 14, 15 In brief obese children and adolescents who had chronically elevated serum aminotransferase levels, or demonstrated a diffusely echogenic change on liver B-ultrasonography (fatty infiltration in liver), however had no demonstrable reason for abnormal serum chemistry values (such as hepatitis virus infection, drug injure and other metabolic disease like Wilson's disease etc.) other than obesity, and therefore were diagnosed to have NAFLD.
Procedures
Physical parameters:
The subjects were evaluated in the morning before 09:00, after an overnight fast of at least 8 h. Height was measured without socks and shoes, and weight was measured whereas the children wore only underclothing. Waist (measure waist at narrowest point) and hip circumference (hip at widest point) ratio were recorded (WHR). Pubertal development stages were assessed using criteria of Tanner stage. Blood pressure (BP) measurements were made using the right arm, with the subject in a quiet sitting position. BP was measured twice and the average recorded.
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Biochemical
parameters: Blood samples were collected in the morning after an overnight fast, with the use of an indwelling venous line for measurement of levels of glucose, insulin, lipids (total triglyceride (TG), total cholesterol (TCHO), HDL-C and low-density lipoprotein cholesterol (LDL-C)), liver function (aspartate aminotransferase AST, alanine aminotransferase ALT) and uric acid. An oral glucose-tolerance test was then performed with the administration of 1.75 g of glucose per kilogram of body weight (maximum 75 g). Adiponectin levels were detected in three groups (Group 1: MS group, Group 2: simple obese subjects, Group 3: healthy controls, n ¼ 36 þ 61 þ 24 ¼ 121). Blood glucose was determined using a glucose oxidase method (Beijing North Biotechnology Company, China) with intra-assay and inter-assay CVs of 2.1 and 4.4%. Insulin serum levels were determined by radioimmunoassay (Beijing North Biotechnology Company, China) with intra-assay and inter-assay CVs of 6.4 and 9.7% respectively. The concentration of serum TCHO and TG, ALT, AST and uric acid were measured by routine enzymatic methods in our clinical laboratory unit. Plasma HDL-C and LDL-C concentration were detected in the Central Laboratory of Radioimmunity in Hangzhou. The serum levels of adiponectin were detected by commercially available ELISA kit (R&D System Incorporation, USA). The intra-and inter-assay CVs of adiponectin ranged from 2.5 to 4.7% and 5.8 to 6.9% respectively. 3. Calculation: Insulin resistances were calculated by the homeostasis model (homeostasis model of insulin resistance (HOMA-IR)) and the whole body insulin sensitive index (WBISI) after glucose tolerance.
4. Lifestyle modification and metformin intervention: All patients received standardized dietary advice from a research dietitian. Each subject received an individual diet sheet with a list of most common foods marked with value of calorie. They were suggested to have high in carbohydrate (50%) and low in fat (10%) with the aim of a reduction in daily intake by 250 kcal. They were also encouraged to have a low-intensity aerobic exercise such as quickly walking, slowly run or string jumping etc to reach 50-60% maximum of their heart beat and maintained for at least 30 min, 2-3 times a week. Thirty out of thirty-six MS subjects aged over 10 years old received metformin (Glucophage, Squibb Pharmacy Company, SASS) treatment at dose of 500 mg bid combined with lifestyle modification. Twenty out of thirty of them who had finished 3-month treatment received the measurements of adiponectin, liver and kidney functions and oral glucose tolerance test (OGTT) again. 10/30 has not finished the course was excluded. 
Results
1.
Three hundred and forty-eight moderately and severely obese children and adolescents aged between 7 and 16 years old were included in this study. Among them, 253 subjects were moderately obese and 95 subjects were severely obese. One hundred and thirty-six out of 348 subjects (n ¼ 79 boys, n ¼ 57 girls) aged between 7 and o10 years old, and 212/348 subjects (n ¼ 129 boys, n ¼ 83 girls) ranged from10 to16 years old. The rationale for dividing the study subjects in two age range subgroups was according to the fact that most subjects were prepubertal (Tanner stage G1PH1) before 10 years old and began to enter puberty after 10 years old. Moreover metformin was only allowed to be used in children and adolescents with age over 10 according to ADA. Table 4 3 Month follow-up Table 2 The relationship between the components of MS and serum adiponectin and WBISI was analyzed in Figure 1 The dispositions of subjects who were recruited and studied are graphically displayed. Three hundred and forty-eight moderately and severely obese children and adolescents aged between 7 and 16 years old were included in this study. Ninety-five subjects were moderately obese and 253 subjects were severely obese. Thirty-six of them (10.34%) meeting at least three of the five criteria qualified as having the MS, 251/348 of subjects (72.13%) have at least one complication, 97/348(27.87%) has more than two complication and only 61/348(17.53) has no complication defined as simple obesity. The incidence of obese complication was displayed in the flow chart.
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The correlation analysis showed that serum levels of adiponectin and WBISI were associated with components of MS (all Po0.05) as shown in Table 3 . 3. Comparison of clinical data before and after metformin treatment and lifestyle modification in obese children and adolescents with MS. Thirty out of thirty-six MS children and adolescents aged over 10 years accepted metformin intervention combined with lifestyle modification. Twenty out of thirty of them has finished 3-month follow-up. There was a significant reduction in BMI, a markedly increased in adiponectin level and ameliorated biochemical factors which are involved in MS after 3-month treatment (Table 4) . During the metformin treatment, seven of them (23.3%) reduced their appetite, two of them (6.7%) felt slight nausea, and another two of them (6.7%) showed increased frequency of bowels movement during the first week of the treatment. No other obvious side effects were noted.
Discussion
Our findings suggested that obesity associated metabolic abnormalities are no longer solely characteristic of the adults. Obesity in children is not just obesity, but is accompanied by co-morbidities that cluster to form the 'MS' just like in the adults. The prevalence of MS in all the moderately and severely obese children and adolescents was Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model of insulin resistance; MS, metabolic syndrome; WBISI, whole body insulin sensitive index; WHR, waist-hip ratio. There was no significant difference in age, gender and pubertal stage among these three groups. BMI, WHR and HOMA-IR increased stepwise (all Po0.01) in the control group, the simple obese group and the MS group, whereas serum adiponectin and WBISI decreased stepwise (all Po0.01). Systolic pressure, TG, TCHO, LDL-C and postprandial 2-h blood glucose in the MS group increased significantly compared to those in the control and the simple obese group, whereas HDL-C was markedly decreased in MS group compared to other two groups. Metabolic syndrome in Chinese obese children and adolescents J-F Fu et al 10.3%, and hit 22.1% in the severely obese subjects. More over, each component of MS worsened with an increased degree of obesity. The data on other Chinese children and adolescent population do not exist to our best knowledge except for one report from Hongkong but it did not take the investigation of MS as its primary goal. 16 There were some data from Japan and USA. The prevalence of MS was 17.7% in Japanese obese elementary school children aged between 6 and 11 years old, 17 and 28.7% in USA in the obese adolescents aged between 12 and 19 years old, 18 and 38.7%
in the moderately obese children and adolescents and 49.7% in the severely obese subjects in USA. 12 As there are no internationally acceptable uniform criteria so far for diagnosing MS in children and adolescents, so the data cannot be compared universally. Therefore at present the only hypotheses to explain this difference are variations in ethnicity, diet and heritage. However our data collectively with other published data all suggested that the prevalence of MS in obese children and adolescents forewarns a rapidly increasing problem in childhood health. In this study, we also found that people aged between 10 and 16 years old with more mature pubertal state had higher MS frequencies than those aged between 7 and 10 years old. This indicated that pubertal insulin resistance might have an effect in adolescent MS development. Observation of pubertal insulin resistance showed that insulin-stimulated glucose metabolism was approximately 30% lower in a sample of children at Tanner stages II-IV compared with children at Tanner stage I. 19 Pubertal insulin resistance occurs during a time of profound changes in body composition and hormone levels. Although obesity beginning in childhood often precedes the hyperinsulinemic state, 20 so obesity should be intervened as early as possible. Though the prevalence of MS was not as high as that which others reported, the incidence of having more than one complication such as hypertension, dyslipidemia, hyperuricemia, NAFLD and glucose intolerance reached 72.13 and 27.87% of obese subjects had at least two of these complications. The prevalence of the type2 diabetes (1.44%) in this study group should also be noticed. This epidemic in obese children and adolescents again urgently needs appropriate intervention. Like adults, insulin resistance 'drives' the process underlying MS. Obese children and adolescents in our study also showed the disease stratified according to the degree of insulin resistance. We can see that HOMA-IR increased stepwise in the control group, the SOB and the MS group, whereas WBISI decreased stepwise. Our previous study and other studies all proved that HOMA-IR and WBISI were valid insulin sensitivity indices from OGTT parameters in obese children and adolescents. 21, 22 Our factor analysis also showed strong negative correlations of WBISI to the degree of obesity (BMI) and the glucose metabolism factor (2-h postprandial sugar) and moderately loading to the dyslipidemia factors (TG, HDL-C), indicating that insulin resistance might play a leading role in developing of MS. One major finding of our study was that adiponectin levels decrease in parallel with the increasing degree of the obesity. As a consequence, adiponectin levels are significantly reduced in MS group compared to the simple obese and control peers. In addition, adiponectin significantly negatively associated with components of MS such as BMI, systolic blood pressure TG, 2-h postprandial blood sugar after oral glucose load, and positively correlated with insulin sensitivity (WBISI) and HDL cholesterol in our cohort. Therefore, adiponectin levels do correlate with important risk factors of insulin resistance and MS in pediatric cohort. In fact, the insulin sensitivity Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; MS, metabolic syndrome; SP, systolic pressure; TG, total triglyceride; WBISI, whole body insulin sensitive index; 2hPG, postprandial 2-h blood glucose. Serum levels of adiponectin and WBISI were negatively associated with BMI, SP, 2hPG and TG, whereas positively associated with HDL-C. Moreover, serum adiponectin was tightly associated with WBISI. Before analysis, values of WBISI and HDL-C were logtransferred. Pearson coefficient was used to express their relationship. Metabolic syndrome in Chinese obese children and adolescents J-F Fu et al index had the strongest influence on adiponectin levels in obese children in the multiple regression models even overriding the influence of pubertal development and BMI in Bottner's study. 23 These results are in accordance with other studies. [24] [25] [26] Interestingly, in our study, the reduction of adiponectin appears to precede the actual development of any complication of obesity as we can see adiponectin levels are significantly lower in simple obese children and adolescents compared to healthy control. These results emphasize that the complete panel of features of the MS may already occurred in childhood. More detailed studies in the pediatric cohort are highly warranted to testify these associations.
Interventions are impressive but not widely studied. 27, 28 Comprehensive behavioral management, dietary modification and enhancement of physical activity are unquestionable prerequisites for long-term success in the management of MS. As MS is characterized by hypertension, dyslipidemia and central adiposity facing early risks of cardiovascular morbidity and mortality, some of them has already developed to type 2 diabetes, and many of them have IGT ('prediabetes'), early use of oral-agent combinations is gaining favor. 29, 30 The only drug evaluated in a formal trial in children is metformin. 31, 32 In this study, after 3 months of metformin therapy and lifestyle modification, the improvement with this combination was evidenced by a significant reduction in BMI, a markedly increased in adiponectin level and insulin sensitivity, and ameliorated biochemical factors which are involved in MS. A study on reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin found that lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin. 33 Therefore, the lifestyle modification should be much stressed in treating the childhood MS apart from metformin treatment. The side effects of metformin in this study were consistent with that reported in adults. 34, 35 Only minor gastrointestinal effects such as increased bowel movement, nausea and reduced appetite were found and such effects typically occurred at the start of treatment with metformin and were significantly reduced with the passage of time. The mechanism of metformin in improving MS in adolescents might be due to the effect of the drug by inhibiting the intestinal glucose absorption, reducing the hepatic glucose production, increasing the insulin sensitivity in peripheral insulin-targeted tissues without increasing insulin secretion. 36, 37 A more large population, placebo-controlled, double-blind and long-term follow-up clinical trial of metformin treatment in adolescents MS are needed in the future study. In a conclusion, the prevalence of MS in Chinese obese children and adolescents especially in severely obese subjects has reached a high level. Insulin resistance and hypoadiponectinemia are characteristic features of MS in children and adolescents. Metformin treatment combined with lifestyle modification was confirmed to be efficient and safe in treating the obese adolescents with MS.
